Peptides and transmitter enzymes in hypothalamic magnocellular neurons after administration of hyperosmotic stimuli: comparison between messenger RNA and peptide/protein levels.
In situ hybridization histochemistry and indirect immunofluorescence histochemistry were used to study changes in the expression of vasopressin (VP), oxytocin (OXY), tyrosine hydroxylase (TH), galanin (GAL), dynorphin (DYN) and cholecystokinin (CCK) in hypothalamic magnocellular neurons of the paraventricular (PVN) and supraoptic (SON) nuclei of rats. After prolonged administration of 2% sodium chloride as drinking water (salt-loading), the treatment increased the levels of VP, OXY, TH, GAL, DYN and CCK mRNA in the PVN and SON. The increase in CCK mRNA was, however, proportionally higher in the PVN than in the SON. Within cell bodies of the PVN and SON of salt-loaded rats, a depletion of VP- and OXY-like immunoreactivity (LI) and an increase in TH-LI were seen. In salt-loaded/colchicine-treated rats, a marked decrease in GAL- and DYN-LI, but no specific changes in CCK-LI were observed. Within nerve fibers of the posterior pituitary of salt-loaded rats, a marked depletion of VP-, GAL- and DYN-LI was found. Less pronounced depletion was observed in OXY- and CCK-LI, and no specific changes in TH-LI were seen. The results show that high plasma osmolality induces increased mRNA levels for VP, OXY, TH, GAL, DYN and CCK, presumably indicating increased synthesis, an increased export from cell somata of VP, OXY, GAL and DYN, and a decrease in levels of these peptides in the posterior pituitary, suggesting increased release. The catecholamine-synthesizing enzyme TH, however, which has a cytoplasmic localization and is not released from nerve endings, remains high in the cell bodies and nerve endings during this state of increased activity.
Meister
B
B
Department of Histology and Neurobiology, Karolinska Institute, Stockholm, Sweden.
Cortés
R
R
Villar
M J
MJ
Schalling
M
M
Hökfelt
T
T
D000284:Administration, Oral; D000818:Animals; D001345:Autoradiography; D002766:Cholecystokinin / Q000235:genetics / Q000378:metabolism; D004399:Dynorphins / Q000235:genetics / Q000378:metabolism; D005455:Fluorescent Antibody Technique; D019004:Galanin; D006982:Hypertonic Solutions; D007031:Hypothalamus / Q000166:cytology* / Q000378:metabolism; D007150:Immunohistochemistry; D008297:Male; D009474:Neurons / Q000201:enzymology* / Q000378:metabolism; D018377:Neurotransmitter Agents / Q000378:metabolism*; D009693:Nucleic Acid Hybridization; D009994:Osmolar Concentration; D010121:Oxytocin / Q000235:genetics / Q000378:metabolism; D010286:Paraventricular Hypothalamic Nucleus / Q000166:cytology / Q000378:metabolism; D010455:Peptides / Q000235:genetics / Q000378:metabolism*; D012333:RNA, Messenger / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D051381:Rats; D011919:Rats, Inbred Strains; D012965:Sodium Chloride / Q000008:administration & dosage / Q000494:pharmacology*; D013495:Supraoptic Nucleus / Q000166:cytology / Q000378:metabolism; D014446:Tyrosine 3-Monooxygenase / Q000235:genetics / Q000378:metabolism; D014667:Vasopressins / Q000235:genetics / Q000378:metabolism
D006982:Hypertonic Solutions; D018377:Neurotransmitter Agents; D010455:Peptides; D012333:RNA, Messenger; D014667:Vasopressins; D012965:Sodium Chloride; D010121:Oxytocin; D004399:Dynorphins; D019004:Galanin; D002766:Cholecystokinin; D014446:Tyrosine 3-Monooxygenase